These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 16339692

  • 1. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
    Grosse R, Lund U, Caruso V, Fischer R, Janka GE, Magnano C, Engelhardt R, Dürken M, Nielsen P.
    Ann N Y Acad Sci; 2005; 1054():429-32. PubMed ID: 16339692
    [Abstract] [Full Text] [Related]

  • 2. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C.
    Eur J Haematol; 2010 Jan 01; 84(1):72-8. PubMed ID: 19732137
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Methods for noninvasive measurement of tissue iron in Cooley's anemia.
    Sheth S, Tang H, Jensen JH, Altmann K, Prakash A, Printz BF, Hordof AJ, Tosti CL, Azabagic A, Swaminathan S, Brown TR, Olivieri NF, Brittenham GM.
    Ann N Y Acad Sci; 2005 Jan 01; 1054():358-72. PubMed ID: 16339684
    [Abstract] [Full Text] [Related]

  • 5. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF, Peng CT, Wu KH, Tsai CH.
    Hemoglobin; 2006 Jan 01; 30(2):215-8. PubMed ID: 16798646
    [Abstract] [Full Text] [Related]

  • 6. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
    al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV.
    Br J Haematol; 1992 Oct 01; 82(2):431-6. PubMed ID: 1419825
    [Abstract] [Full Text] [Related]

  • 7. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z, Fischer R, Treadwell M, Yamashita R, Fung EB, Calvelli L, Quirolo K, Foote D, Harmatz P, Vichinsky EP.
    Ann N Y Acad Sci; 2005 Oct 01; 1054():486-91. PubMed ID: 16339703
    [Abstract] [Full Text] [Related]

  • 8. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
    Moayedi B, Gharagozloo M, Esmaeil N, Maracy MR, Hoorfar H, Jalaeikar M.
    Eur J Haematol; 2013 Mar 01; 90(3):202-9. PubMed ID: 23278124
    [Abstract] [Full Text] [Related]

  • 9. No evidence for myocardial iron overload and free iron species in multitransfused patients with sickle/beta-thalassaemia.
    Ghoti H, Goitein O, Koren A, Levin C, Kushnir T, Rachmilewitz E, Konen E.
    Eur J Haematol; 2010 Jan 01; 84(1):59-63. PubMed ID: 19793250
    [Abstract] [Full Text] [Related]

  • 10. Iron metabolism in thalassemia intermedia.
    Fiorelli G, Fargion S, Piperno A, Battafarano N, Cappellini MD.
    Haematologica; 1990 Jan 01; 75 Suppl 5():89-95. PubMed ID: 2086386
    [Abstract] [Full Text] [Related]

  • 11. Pathogenesis and management of iron toxicity in thalassemia.
    Hershko C.
    Ann N Y Acad Sci; 2010 Aug 01; 1202():1-9. PubMed ID: 20712765
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.
    Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW.
    N Engl J Med; 1994 Sep 01; 331(9):567-73. PubMed ID: 8047080
    [Abstract] [Full Text] [Related]

  • 13. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
    Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E.
    Haematologica; 2007 May 01; 92(5):583-8. PubMed ID: 17488680
    [Abstract] [Full Text] [Related]

  • 14. Fluorescence assay of non-transferrin-bound iron in thalassemic sera using bacterial siderophore.
    Sharma M, Saxena R, Gohil NK.
    Anal Biochem; 2009 Nov 15; 394(2):186-91. PubMed ID: 19632191
    [Abstract] [Full Text] [Related]

  • 15. Increased levels of advanced glycation end products positively correlate with iron overload and oxidative stress markers in patients with β-thalassemia major.
    Mirlohi MS, Yaghooti H, Shirali S, Aminasnafi A, Olapour S.
    Ann Hematol; 2018 Apr 15; 97(4):679-684. PubMed ID: 29318368
    [Abstract] [Full Text] [Related]

  • 16. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P, Grady RW, Dragsten P, Vichinsky E, Giardina P, Madden J, Jeng M, Miller B, Hanson G, Hedlund B.
    Br J Haematol; 2007 Aug 15; 138(3):374-81. PubMed ID: 17614825
    [Abstract] [Full Text] [Related]

  • 17. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin.
    Gosriwatana I, Loreal O, Lu S, Brissot P, Porter J, Hider RC.
    Anal Biochem; 1999 Sep 10; 273(2):212-20. PubMed ID: 10469492
    [Abstract] [Full Text] [Related]

  • 18. Heart Rate Variability for Early Detection of Iron Overload Cardiomyopathy in β-Thalassemia Patients.
    Koonrungsesomboon N, Tantiworawit A, Phrommintikul A, Saekho S, Srichairattanakool S, Chattipakorn N.
    Hemoglobin; 2015 Sep 10; 39(4):281-6. PubMed ID: 26029793
    [Abstract] [Full Text] [Related]

  • 19. Removal of non-transferrin-bound iron from blood with iron overload using a device with immobilized desferrioxamine.
    Ambrus CM, Stadler I, Toumbis CA, Stadler A, Anthone S, Anthone R, DeAlarcon P, Deshpande G, Conway J, Vladutiu AO, Ambrus JL.
    J Med; 1999 Sep 10; 30(3-4):211-24. PubMed ID: 17312675
    [Abstract] [Full Text] [Related]

  • 20. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ, Göbel U, Christaras A, Janssen G.
    Klin Padiatr; 2005 Sep 10; 217(3):120-5. PubMed ID: 15858702
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.